-
venBio is a life sciences investment firm that partners with industry leaders to build game-changing medicines and technologies, with a focus on novel therapeutics for unmet medical needs.
Latest News
-
2019
19JUNAkero Therapeutics Announces Pricing of Initial Public Offering
posted by admin in Latest NewsAkero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH)...
Read More -
2019
17APRTurning Point Therapeutics prices IPO at $18, the high end of the range
posted by admin in Latest NewsTurning Point Therapeutics, an early stage biotech developing tyrosine kinase inhibitors for treating cancer, raised $167 million by offering 9.3 million shares at $18, the high end of the range of $16 to $18.
Read More -
2019
27MARPrecision BioSciences Announces Pricing of Initial Public Offering
posted by admin in Latest NewsPrecision BioSciences (Nasdaq:DTIL) ("Precision"), a genome editing company dedicated to improving life ( DTIL ) through its proprietary ARCUS genome editing platform, today announced the pricing of its initial public offering of 7,900,000 shares of common stock at a public offering price of $16.00 per share...
Read More -
2019
12FEBHarmony Biosciences Announces File Acceptance Of Its New Drug Application For Pitolisant
posted by admin in Latest NewsHarmony Biosciences, LLC (Harmony), announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for its investigational product, pitolisant, and has granted Priority Review for this NDA.
Read More